Global Acute Myeloid Testing Market – Industry Trends and Forecast to 2027

  • Medical Devices
  • Upcoming Report
  • Nov 2019
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Acute Myeloid Testing Market By Biomarker Type (Genetic AML Biomarker, Epigenetic AML Biomarker, Proteomic AML Biomarker), Product & Service (Services, Assay Kits), Technology (PCR, IHC, NGS, Cytogenetics, Others), End User (Clinical Laboratories, Hospitals, Academic & Research Institutes, Cancer Diagnostic Institutes, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa), Market Trends and Forecast to 2027

Market Analysis and Insights: Global Acute Myeloid Testing Market

Global acute myeloid testing market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 1,218.43 million by 2027 growing at a healthy CAGR of 13.70% in the above-mentioned forecast period. The growth of this market is owing to multiple factors, one of which is the increasing prevalence of collaborations and partnerships between various market players whether that is diagnostic manufacturers or even therapeutic manufacturers.

The growing incidence of the aging population in combination with growing population prevalence for acute myeloid leukemia are one of the major factors enhancing the growth rate for acute myeloid testing market, the factors along with innovations in terms of product offerings and services by the major manufacturers such as in August 2018, Abbott had recently received the U.S. FDA’s approval for their “RealTime IDH1”. The approval was provided for the diagnostic test intended for detection of mutations specific to acute myeloid leukemia disease. These factors are expected to add a significant trend for the growth of the market in the forecast period of 2020 to 2027.

This market report provides details of market share, new developments, product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief our team will help you create a revenue impact solution to achieve your desired goal.

Global Acute Myeloid Testing Market Scope and Market Size

Global acute myeloid testing market is segmented on the basis of biomarker type, product & service, technology and end user. The growth among segments helps the users analyse niche pockets of growth and assists them in devising strategies for their businesses and determine your core application areas amongst the differences in specific target markets.

Based on biomarker type the market is segmented into genetic acute myeloid leukemia (AML) biomarker, epigenetic acute myeloid leukemia (AML) biomarker, proteomic acute myeloid leukemia (AML) biomarker. Genetic AML biomarker segment has been further segmented into FLT3, NPM1, TP53, MU-AML and others. Epigenetic AML biomarker has also been segmented into IDH1/2, TET and DNMT3A. Proteomic AML biomarker has been segmented as HNRH1, CALR, FIBA and HSP.

Based on the product & service it covers services and assay kits.

Based on technology the market has been segmented into PCR (Polymerase Chain Reaction), IHC (Immunohistochemistry), NGS (Next-Generation Sequencing), cytogenetics and others.

Global acute myeloid testing market has also been segmented on the basis of end user, it is categorized as clinical laboratories, hospitals, academic & research institutes, cancer diagnostic institutes and others.

Acute Myeloid Testing Market Country Level Analysis

Global acute myeloid testing market analyses and market size information is provided by country by biomarker type, product & service, technology and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific in the Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa as a part of Middle East and Africa, Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market due to the large scale prevalence of the target disorder in the region although Asia-Pacific is expected to witness the largest growth rate out of all the regions with the growing volume of patients suffering from this disorder increasing in the region along with the focus of established players to expand their prevalence in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands impact of sales channels are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Global acute myeloid testing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for acute myeloid testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the acute myeloid testing market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Acute Myeloid Testing Market Share Analysis

Global acute myeloid testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to acute myeloid testing market.

The major players covered in the report are NeoGenomics Laboratories, Inc., QIAGEN, Invivoscribe, Inc., Illumina, Inc., ArcherDx, Inc., ARUP Laboratories, ASURAGEN, INC., Mayo Foundation for Medical Education and Research, Laboratory Corporation of America Holdings, Dr Lal PathLabs, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Thermo Fisher Scientific Inc., Cancer Genetics Inc., SkylineDx B.V. among other players domestic and global. Market Share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

In October 2019, Invivoscribe, Inc. announced that Asetallas’ “XOSPATA” a therapeutic designed for the treatment of relapsed or refractory acute myeloid leukemia (AML) had received European Commission’s approval. This drug was approved by the authority based on the detection of AML in patients suffering from FLT3 mutations with the help of Invivoscribe, Inc.’s “LeukoStrat CDx FLT3 Mutation Assay”. These partnerships between various diagnostic technology providers and pharmaceutical organizations are one of the major growth factors for global acute myeloid testing market.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies we can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

Please fill in the below form for detailed List of Table

Please fill in the below form for detailed List of Figure

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19